Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

Autor: Brian J. Thomas, Sania Z. Awan, Trupti Joshi, Mark A. Daniels, David Porciani, Donald H. Burke

Publikováno v: npj Precision Oncology, Vol 8, Iss 1, Pp 1-17 (2024)

Abstract Non-small cell lung cancer (NSCLC) adenocarcinoma (LUAD) is a leading cause of death worldwide. Activating mutations in the tyrosine kinase domain of the oncogene epidermal growth factor receptor (EGFR) are responsible for ~10–50% of all L

Externí odkaz: https://doaj.org/article/19ded60ddac442009ca73cf4d272ce93

First case report of erlotinib plus ramucirumab treatment for lung carcinosarcoma with EGFR L858R mutation

Autor: Naoya Ishibashi, Toshiharu Tabata, Ryo Nonomura, Yutaka Oshima, Takanobu Sasaki, Hideki Mitomo, Takafumi Sugawara, Motoyasu Sagawa

Publikováno v: Thoracic Cancer, Vol 14, Iss 34, Pp 3415-3418 (2023)

Abstract Lung carcinosarcoma is acknowledged as a rare form of lung cancer. Due to its rarity, the inability to conduct large‐scale clinical trials and interventions is currently carried out based on empirical evidence. In this study, we report the

Externí odkaz: https://doaj.org/article/72def1835b254b798045913ba7ba8812

High throughput virtual screening and validation of Plant-Based EGFR L858R kinase inhibitors against Non-Small cell lung Cancer: An integrated approach Utilizing GC–MS, network Pharmacology, Docking, and molecular dynamics

Autor: Kun Gao, Zujian Chen, Na Zhang, Pu Jiang

Publikováno v: Saudi Pharmaceutical Journal, Vol 32, Iss 9, Pp 102139- (2024)

Lung cancer ranks as the 2nd most common cancer globally. It’s the most prevalent cancer in men and the 2nd most common in women. The prominent events in EGFR-mutated non-small-cell lung cancer (NSCLC) include the emergence of the L858R mutation wi

Externí odkaz: https://doaj.org/article/fc98266850544300967cd2cf83a73869

An acquired CCDC6:: RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R) -mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature.

Autor: Lormans M; Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium., Van Haecke P; Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium., Demedts I; Department of Pulmonary Diseases, AZ Delta, Roeselare, Belgium.

Publikováno v: Journal of chemotherapy (Florence, Italy) [J Chemother] 2025 Jan 05, pp. 1-6. Date of Electronic Publication: 2025 Jan 05.

Durable response to afatinib rechallenge in a long‐term survivor of non‐small cell lung cancer harboring EGFR L858R and L747V mutations.

Autor: Kanbe, Mio¹ (AUTHOR), Sunaga, Noriaki¹ (AUTHOR) nsunaga@gunma-u.ac.jp, Hara, Kenichiro¹ (AUTHOR), Sawada, Hiiru¹ (AUTHOR), Wakamatsu, Ikuo¹ (AUTHOR), Hara, Kentaro¹ (AUTHOR), Muto, Sohei¹ (AUTHOR), Sawada, Yuri¹ (AUTHOR), Masubuchi, Hiroaki¹ (AUTHOR), Sato, Mari¹ (AUTHOR), Miura, Yosuke¹ (AUTHOR), Tsurumaki, Hiroaki¹ (AUTHOR), Yatomi, Masakiyo¹ (AUTHOR), Sakurai, Reiko² (AUTHOR), Koga, Yasuhiko¹ (AUTHOR), Ohtaki, Yoichi³ (AUTHOR), Nagashima, Toshiteru³ (AUTHOR), Okano, Naoko⁴ (AUTHOR), Kubo, Nobuteru⁴ (AUTHOR), Maeno, Toshitaka¹ (AUTHOR)

Publikováno v: Thoracic Cancer. Nov2022, Vol. 13 Issue 22, p3225-3228. 4p.